{"id":"NCT00091507","sponsor":"Tufts Medical Center","briefTitle":"IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.","officialTitle":"Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2011-08","completion":"2012-08","firstPosted":"2004-09-13","resultsPosted":"2013-01-30","lastUpdate":"2016-03-02"},"enrollment":911,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Angina, Unstable","Cardiovascular Diseases","Heart Diseases","Coronary Disease","Myocardial Infarction","Heart Failure, Congestive"],"interventions":[{"type":"DRUG","name":"GIK","otherNames":["Glucose-Insulin Potassium"]},{"type":"DRUG","name":"Placebo","otherNames":["Dextrose 5%"]}],"arms":[{"label":"1 -- GIK","type":"EXPERIMENTAL"},{"label":"2 -- Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established acute myocardial infarction (AMI).","primaryOutcome":{"measure":"Progression of Acute Coronary Syndrome to Myocardial Infarction","timeFrame":"24 hours","effectByArm":[{"arm":"GIK --","deltaMin":200,"sd":null},{"arm":"Placebo","deltaMin":242,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.28"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["21366431","22424000","26644202","25778467","26631004","26193887","22452807","24792735","24686107","24425697"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":411},"commonTop":["Hyperglycaemia","Injection site reaction","Ventricular extrasystoles","Hypotension","Ventricular tachycardia"]}}